Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 9, 2013
Grant Date -
Oct 27, 2005
app pub date -
Mar 11, 2004
filing date -
Mar 12, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Composition and method for stimulating angiogenesis, stimulating myogenesis, upregulating angiogenic factors and angiopoietins, and treating the muscular and vascular complications of diabetes. Overall, the embodiments of the invention can be accomplished by delivering a heterologous nucleic acid sequence encoding insulin-like growth factor I (“IGF-I”) or a functional biological equivalent thereof into the cells of the subject and allowing expression of the encoded gene to occur while the modified cells are within the subject. The nucleic acid sequence maybe delivered by a vector system including a synthetic myogenic promoter and a 3′ untranslated region. The preferred method to deliver the constitutive or inducible nucleic acid encoding sequences of IGF-I or the functional biological equivalents thereof is directly into the cells of the subject by the process of in vivo electroporation.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully